In similar with gilteritinib, quizartinib improved the anti-cancer effect of abemaciclib in lung cancer cells (Supplementary Figure S1C), indicating that FLT3 might confer synthetic lethality to CDK4/6 inhibition. Here, FLT3 is linked to lung cancer.